78 related articles for article (PubMed ID: 27012192)
1. IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2.
Merz C; von Mässenhausen A; Queisser A; Vogel W; Andrén O; Kirfel J; Duensing S; Perner S; Nowak M
Am J Pathol; 2016 Apr; 186(4):974-84. PubMed ID: 27012192
[TBL] [Abstract][Full Text] [Related]
2. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
[TBL] [Abstract][Full Text] [Related]
3. EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer.
Kashiwagi E; Shiota M; Yokomizo A; Inokuchi J; Uchiumi T; Naito S
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):10-7. PubMed ID: 24518515
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
[TBL] [Abstract][Full Text] [Related]
5. Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer.
Huang HF; Shu P; Murphy TF; Aisner S; Fitzhugh VA; Jordan ML
Mol Cancer Res; 2013 Apr; 11(4):427-39. PubMed ID: 23364535
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis.
Miyata Y; Ohba K; Matsuo T; Watanabe S; Hayashi T; Sakai H; Kanetake H
Urology; 2013 Jan; 81(1):136-42. PubMed ID: 23149328
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
11. VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC; Khosrawi P; Weigand P; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Krech T; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S
Int J Mol Sci; 2015 Apr; 16(4):8591-606. PubMed ID: 25894226
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
[TBL] [Abstract][Full Text] [Related]
14. SNW1 is a prognostic biomarker in prostate cancer.
Höflmayer D; Willich C; Hube-Magg C; Simon R; Lang D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Huland H; Graefen M; Haese A; Heinzer H; Minner S; Büscheck F; Sauter G; Schlomm T; Steurer S; Clauditz TS; Burandt E; Wilczak W; Bernreuther C
Diagn Pathol; 2019 May; 14(1):33. PubMed ID: 31043167
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 suppresses poly I: C-stimulated cytokine production via EP2 and EP3 in immortalized human corneal epithelial cells.
Ueta M; Matsuoka T; Sotozono C; Kinoshita S
Cornea; 2012 Nov; 31(11):1294-8. PubMed ID: 22475642
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
[TBL] [Abstract][Full Text] [Related]
17. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
18. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERG protein in prostate cancer: variability and biological correlates.
Ayala G; Frolov A; Chatterjee D; He D; Hilsenbeck S; Ittmann M
Endocr Relat Cancer; 2015 Jun; 22(3):277-87. PubMed ID: 25972242
[TBL] [Abstract][Full Text] [Related]
20. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
